The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort
Abstract
Because there are little satisfactory data on change in severity of diabetic polyneuropathy (DP) over time from study of population-based cohorts of diabetic patients in epidemiologic surveys of DP, it is difficult to predict outcome or morbidity or to identify risk factors; it is also difficult to estimate statistical power for use in controlled clinical trials. In this longitudinal study of almost 200 patients from the Rochester Diabetic Neuropathy Study (RDNS) cohort, we assess which symptoms, clinical examinations, tests, or combinations of examinations and tests (composite scores) are best used as minimal criteria for the diagnosis of DP and as a quantitative measure of severity of DP. An abnormality (> or = 97.5th percentile) of a composite score that included the Neuropathy Impairment Score of the lower limbs plus seven tests (NIS(LL)+7 tests), was a better minimal criteria for DP than clinical judgment alone or previously published minimal criteria. First, it provided a more comprehensive assessment of neuropathic impairment. Second, it avoided the overestimated frequency of DP when the minimal criteria for DP was any one or two abnormalities from multiple measurements. Minimal criteria using nerve conduction and reduced heart beat response to deep breathing identified approximately twice as many patients with DP than did clinical examination and vibration detection threshold using CASE IV. This difference could be used to subclassify state 1 DP. Although various individual measures of DP, for example, vibration detection threshold (as evaluated by CASE IV and the 4, 2, and 1 stepping algorithm [see text]), were good measures of worsening, the composite score NIS(LL)+7 tests (assessing neuropathic impairment) was much better at showing monotone worsening. Using this composite score, the average diabetic patient in the RDNS worsened by 0.34 points per year, whereas patients with diabetic polyneuropathy worsened by 0.85 points per year. On the assumption that a therapeutic agent may prevent worsening of DP but not cause improvement, controlled clinical trials of patients with DP would need to be conducted for a period of 3 years to achieve a meaningful change of 2 NIS points (the level of abnormality considered by a Peripheral Nerve Society consensus group to be clinically meaningful).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Effect of Intensive Diabetes Therapy on the Development and Progression of Neuropathy
The Diabetes Control and Complications Trial Research Group. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-8-199504150-00001 · Cited by 602
Dyck, P. J., Litchy, W. J., Kratz, K. M., Suarez, G. A., Low, P. A., Pineda, A. A., Windebank, A. J., Karnes, J. L., & O'Brien, P. C. (1994) · Annals of Neurology · doi:10.1002/ana.410360607 · Cited by 471
Self-citationNeurosurgical horizons in Parkinson's disease
Goetz, C. G., De Long, M. R., Penn, R. D., & Bakay, R. A. E. (1993) · Neurology · doi:10.1212/wnl.43.1_part_1.1 · Cited by 405
Autosomal dominant cerebellar phenotypes: The genotype has settled the issue
Rosenberg, R. N. (1995) · Neurology · doi:10.1212/wnl.45.1.1 · Cited by 402
Assessment [RETIRED]: Magnetoencephalography (MEG)
(1992) · Neurology · doi:10.1212/wnl.42.1.1 · Cited by 232
Rogers, R. L., Meyer, J. S., Mortel, K. F., Mahurin, R. K., & Judd, B. W. (1986) · Neurology · doi:10.1212/wnl.36.1.1 · Cited by 218
Neurosarcoidosis: Progress and clinical aspects
Scott, T. F. (1993) · Neurology · doi:10.1212/wnl.43.1_part_1.8 · Cited by 187
Giannini, C., & Dyck, P. J. (1995) · Annals of Neurology · doi:10.1002/ana.410370412 · Cited by 165
Self-citationLong-term follow-up evaluation of blood glucose awareness training
Cox, D. J., Gonder-Frederick, L., Julian, D. M., & Clarke, W. (1994) · Diabetes Care · doi:10.2337/diacare.17.1.1 · Cited by 143
Palumbo, P. J., Elveback, L. R., & Whisnant, J. P. (1978) · PubMed · Cited by 122
Amthor, K.-F., Dahl‐Jørgensen, K., Tj, B., Heier, M., Sandvik, L., Aagen�s, �., & Hanssen, K. F. (1994) · Diabetologia · doi:10.1007/bf00403376 · Cited by 110
The Prevalence of Diabetic Distal Sensory Neuropathy in an English Community
Walters, D., Catling, W., Mullee, M., & Hill, R. D. (1992) · Diabetic Medicine · doi:10.1111/j.1464-5491.1992.tb01795.x · Cited by 108
G Proteins and Modulation of Insulin Secretion
Robertson, R. P., Seaquist, E. R., & Walseth, T. F. (1991) · Diabetes · doi:10.2337/diab.40.1.1 · Cited by 101
Gliedman, M. L., TELLIS, V. A., Soberman, R. J., et al. (1978) · Diabetes Care · doi:10.2337/diacare.1.1.1 · Cited by 75
Tolrestat for Mild Diabetic Neuropathy: A 52-Week, Randomized, Placebo-Controlled Trial
Giugliano, D., Marfella, R., Quatraro, A., Rosa, N. D., Salvatore, T., Cozzolino, D., Ceriello, A., & Torella, R. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-1-199301010-00002 · Cited by 56
The history of scabies in veterinary and human medicine from biblical to modern times
Roncalli, R. A. (1987) · Veterinary Parasitology · doi:10.1016/0304-4017(87)90104-x · Cited by 50
Hillson, R. M., Hockaday, T. D. R., & NEWTON, D. J. (1984) · Diabetologia · doi:10.1007/bf00281118 · Cited by 37
Chlorpropamide ? alcohol flush: the case in favour
Johnston, C., Wiles, P. G., & Pyke, D. A. (1984) · Diabetologia · doi:10.1007/bf00252253 · Cited by 13
(1990) · Diabetes Care · doi:10.2337/diacare.13.1.s7 · Cited by 3
Cited by
Boulton, A. J. M., Malik, R. A., Arezzo, J. C., & Sosenko, J. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1458 · Cited by 913
Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
Coelho, T., Maia, L. F., Martins da Silva, A., Waddington Cruz, M., Planté-Bordeneuve, V., Lozeron, P., Suhr, O. B., Campistol, J. M., Conceição, I. M., Schmidt, H. H.-J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661eb1 · Cited by 816
Repurposing Diflunisal for Familial Amyloid Polyneuropathy: A Randomized Clinical Trial
Berk, J. L., Suhr, O. B., Obici, L., Sekijima, Y., Zeldenrust, S. R., Yamashita, T., Heneghan, M. A., Gorevic, P. D., Litchy, W. J., Wiesman, J. F., et al. (2013) · JAMA · doi:10.1001/jama.2013.283815 · Cited by 708
Self-citationRichardson, P. G., Briemberg, H., Jagannath, S., Wen, P. Y., Barlogie, B., Berenson, J., Singhal, S., Siegel, D. S., Irwin, D., Schuster, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7779 · Cited by 649
Lifestyle intervention for pre-diabetic neuropathy
Smith, A. G., Russell, J., Feldman, E. L., Goldstein, J., Peltier, A., Smith, S., Hamwi, J., Pollari, D., Bixby, B., Howard, J., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0224 · Cited by 585
Metadata
- Authors
- Dyck, P. J., Davies, J. L., Litchy, W. J., & O'Brien, P. C.
- Venue
- Neurology
- Published
- 1997-07
- Volume
- 49
- Issue
- 1
- Pages
- 229-239
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2053096937
- Cited by
- 382
- References
- 20
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.